Kimia Biosciences Ltd

Kimia Biosciences Ltd operates with a capital structure that shows a high debt-to-equity ratio of 3.95, indicating a significant reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.92, suggesting limited short-term liquidity to cover immediate liabilities. The company's return on equity (ROE) is 96.45%, which is strong, but its return on assets (ROA) is 8.64%, indicating that the company is not efficiently utilizing its assets to generate returns. In terms of profitability, Kimia Biosciences Ltd has a gross profit of INR 421.38 million and an operating income of INR 168.71 million, translating to a gross margin of 35.43% and an operating margin of 14.19%. These figures are to be compared against the industry's preferred metrics, which typically emphasize high gross margins and efficient cost management. The company's net income of INR 96.12 million reflects a net margin of 8.08%, which is a key indicator of its profitability. The company's revenue is primarily concentrated in the manufacturing of bulk drugs, with a focus on Commercial APIs and Commercial KSMs, Intermediates, and Reagents. There is no detailed segment or geographic breakdown provided in the input data, but the company's operations are based in India, and its products are likely distributed globally. The lack of geographic diversification could pose a concentration risk. Kimia Biosciences Ltd's growth trajectory is not explicitly detailed in the input data, but the company's operating cash flow of INR 213.14 million and free cash flow of INR 83.92 million suggest a positive cash flow generation. The capital expenditure of INR -45.99 million indicates that the company is not investing heavily in new projects or expansions, which could affect its long-term growth potential. The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates potential liquidity constraints. The company's debt-to-equity ratio of 3.95 suggests a high financial leverage, which could increase financial risk in periods of economic downturn. Recent events and filings are not detailed in the input data, but the company's financial snapshot and risk assessment provide insights into its current financial health. The company's reliance on debt financing and its liquidity position are critical factors to monitor for potential changes in its financial strategy.